Pharmaceutical Stocks To Consider – March 25th
Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...
The Quad-City Times1d
Work requirements for Iowa’s expanded Medicaid population approved by Republicans
Under the proposed legislation, most physically able participants in the Iowa Health and Wellness Plan would be required to ...
CW39 Houston5d
Is ‘microdosing’ Ozempic becoming a trend?
The injectable drug and others like it have become extremely popular in recent years as a way to manage diabetes and lose a significant weight. In recent months, it’s become desirable among those who ...
Zepbound copycats remain online despite FDA ban
Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
DXL CEO says big-and-tall retailer could benefit from GLP-1 drugs
Men's big-and-tall retailer DXL is expecting, perhaps ironically, to benefit from the popularity of GLP-1 drugs such as ...
Eli Lilly’s weight-loss drug Mounjaro comes to India, eyes big market with increasing obesity and diabetes risk
Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. The launch ...
The Telegraph7d
Eli Lilly beats Novo Nordisk to launch diabetes and weight-loss drug Mounjaro in India, at $50 for 5 mg vial
up from 20.6% of women and 19% of men in 2015-2016. Lilly's Mounjaro, chemically known as tirzepatide, is currently sold in ...
The Print8d
Eli Lilly launches weight-loss drug Mounjaro in India at $50 for 5 mg vial, beating Novo Nordisk
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...